BlackThorn Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted medicines for the treatment of central nervous system (CNS) disorders. With pathfinder™, our computational psychiatry platform, our approach is based on generating a quantitative, brain-based understanding of neurobehavioral disorders. These data-driven insights are applied to create treatments targeted to biologically-based subtypes of patients to increase the precision of therapeutic intervention. Our clinical pipeline is designed to restore balance to dysregulated brain circuits and empower individuals with CNS disorders to live better lives. BlackThorn is headquartered in San Francisco, California. For more information, please visit blackthornrx.com.
Total Funding: $138,000,000
Funding Stage: Series B
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2015
